메뉴 건너뛰기




Volumn 30, Issue 4, 2010, Pages 266-271

Assessment of eptifibatide clearance by hemodialysis using an in vitro system

Author keywords

End stage renal disease; Eptifibatide; Hemodialysis; Pharmacokinetics

Indexed keywords

EPTIFIBATIDE;

EID: 78149319897     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320766     Document Type: Article
Times cited : (6)

References (18)
  • 1
    • 74549127100 scopus 로고    scopus 로고
    • US Renal Data System. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
    • US Renal Data System, USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2009.
    • (2009) USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States
  • 2
    • 0031733696 scopus 로고    scopus 로고
    • Clinical epidemiology of cardiovascular disease in chronic renal disease
    • Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(suppl 3):S112-S119.
    • (1998) Am J Kidney Dis , vol.32 , Issue.SUPPL. 3
    • Foley, R.N.1    Parfrey, P.S.2    Sarnak, M.J.3
  • 3
    • 0141468244 scopus 로고    scopus 로고
    • Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
    • DOI 10.1161/01.CIR.0000095676.90936.80
    • Sarnak, MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, Mc- Cullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169. (Pubitemid 37337595)
    • (2003) Circulation , vol.108 , Issue.17 , pp. 2154-2169
    • Sarnak, M.J.1    Levey, A.S.2    Schoolwerth, A.C.3    Coresh, J.4    Culleton, B.5    Hamm, L.L.6    McCullough, P.A.7    Kasiske, B.L.8    Kelepouris, E.9    Klag, M.J.10    Parfrey, P.11    Pfeffer, M.12    Raij, L.13    Spinosa, D.J.14    Wilson, P.W.15
  • 4
    • 23844465424 scopus 로고    scopus 로고
    • K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients
    • K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 2005; 45: 16-153.
    • (2005) Am J Kidney Dis , vol.45 , pp. 16-153
  • 5
    • 4143100834 scopus 로고    scopus 로고
    • Aggrastat Somerset, NJ, Medicure Pharma Inc
    • Aggrastat: Package Insert. Somerset, NJ, Medicure Pharma Inc, 2008.
    • (2008) Package Insert
  • 6
    • 78651070522 scopus 로고    scopus 로고
    • Kenilworth, NJ, Schering-Plough Corporation
    • Integrilin: Package Insert. Kenilworth, NJ, Schering-Plough Corporation, 2009.
    • (2009) Integrilin: Package Insert
  • 8
    • 0242593750 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin
    • Gretler DD: Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin Ther 2003; 25: 2564-2574.
    • (2003) Clin Ther , vol.25 , pp. 2564-2574
    • Gretler, D.D.1
  • 9
    • 1042292025 scopus 로고    scopus 로고
    • Evaluation of an in vitro dialysis system to predict drug removal
    • Hudson JQ, Comstock TJ, Feldman GM: Evaluation of an in vitro dialysis system to predict drug removal. Nephrol Dial Transplant 2004; 19: 400-405.
    • (2004) Nephrol Dial Transplant , vol.19 , pp. 400-405
    • Hudson, J.Q.1    Comstock, T.J.2    Feldman, G.M.3
  • 10
    • 1842689870 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function
    • Gretler DD, Guerciolini R, Williams PJ: Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function. Clin Ther 2004; 26: 390-398.
    • (2004) Clin Ther , vol.26 , pp. 390-398
    • Gretler, D.D.1    Guerciolini, R.2    Williams, P.J.3
  • 12
    • 33847361187 scopus 로고    scopus 로고
    • Gambro Polyflux H Dialyzer. Lakewood Gambro
    • Gambro Polyflux H Dialyzer: Package Insert. Lakewood, Gambro, 2006.
    • (2006) Package Insert
  • 13
    • 14644410510 scopus 로고    scopus 로고
    • Fresenius F160. Waltham, Fresenius Medical Care
    • Fresenius F160: Package Insert. Waltham, Fresenius Medical Care, 2004.
    • (2004) Package Insert
  • 15
    • 0036122627 scopus 로고    scopus 로고
    • The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors
    • Jennings LK, Jacoski MV, White MM: The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol 2002; 15: 45-60.
    • (2002) J Interv Cardiol , vol.15 , pp. 45-60
    • Jennings, L.K.1    Jacoski, M.V.2    White, M.M.3
  • 17
    • 0035147041 scopus 로고    scopus 로고
    • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention
    • Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, Glazer S, Tcheng JE: Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 2001; 141: 226-233.
    • (2001) Am Heart J , vol.141 , pp. 226-233
    • Madan, M.1    Berkowitz, S.D.2    Christie, D.J.3    Jennings, L.K.4    Smit, A.C.5    Sigmon, K.N.6    Glazer, S.7    Tcheng, J.E.8
  • 18
    • 0042165874 scopus 로고    scopus 로고
    • Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: Prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis
    • Sperling RT, Pinto DS, Ho KK, Carrozza JP Jr: Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis. Catheter Cardiovasc Interv 2003; 59: 459-462.
    • (2003) Catheter Cardiovasc Interv , vol.59 , pp. 459-462
    • Sperling, R.T.1    Pinto, D.S.2    Ho, K.K.3    Carrozza Jr., J.P.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.